Siponimod
FDA-approved product (tablet, oral), marketed as Mayzent, Siponimod.
- Registered studies
- 33
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Multiple sclerosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Sphingosine-1-phosphate (s1p) receptor modulators
- FDA pharmacologic class
- Sphingosine 1-phosphate Receptor Modulator FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
33registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Siponimod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
NCT04593927 · start 2020-10-28
Registered record
- Registry ID
- NCT04593927
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Mayzent
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2020-10-28
- Completion
- 2023-08-30
- Enrolment
- 451
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSecondary Progressive Multiple Sclerosis (SPMS)InterventionMayzentPhaseNot recordedRegistry statusCompletedMayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
NCT05826028 · start 2020-07-09
Registered record
- Registry ID
- NCT05826028
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2020-07-09
- Completion
- 2022-04-20
- Enrolment
- 368
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSecondary Progressive Multiple SclerosisInterventionNot recordedPhaseNot recordedRegistry statusCompletedSafety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
NCT03623243 · start 2019-02-14
Registered record
- Registry ID
- NCT03623243
- Conditions
- Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis
- Interventions
- Siponimod
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-02-14
- Completion
- 2022-07-06
- Enrolment
- 185
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple SclerosisInterventionSiponimodPhasePhase 3Registry statusCompletedDetermining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
NCT03535298 · start 2019-01-03
Registered record
- Registry ID
- NCT03535298
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Early Highly Effective Therapies Group; Escalation Therapies Group
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2019-01-03
- Completion
- 2027-07-30
- Enrolment
- 800
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Sclerosis, Relapsing-RemittingInterventionEarly Highly Effective Therapies Group; Escalation Therapies GroupPhasePhase 4Registry statusActive not recruitingTraditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
NCT03500328 · start 2018-05-02
Registered record
- Registry ID
- NCT03500328
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2018-05-02
- Completion
- 2026-09
- Enrolment
- 900
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Sclerosis, Relapsing-RemittingInterventionNatalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, PonesimodPhaseNot applicableRegistry statusActive not recruitingEfficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
NCT03338998 · start 2017-12-24
Registered record
- Registry ID
- NCT03338998
- Conditions
- Hemorrhagic Stroke; Intracerebral Hemorrhage (ICH)
- Interventions
- BAF312 solution; Matching Placebo for BAF312 solution; BAF312 tablet; Matching Placebo for BAF312 tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2017-12-24
- Completion
- 2020-05-13
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemorrhagic Stroke; Intracerebral Hemorrhage (ICH)InterventionBAF312 solution; Matching Placebo for BAF312 solution; BAF312 tablet; Matching Placebo for BAF312 tabletPhasePhase 2Registry statusCompletedMechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
NCT02330965 · start 2014-12
Registered record
- Registry ID
- NCT02330965
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Blood Draw; CSF collection by lumbar puncture (Optional)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2017-07-12
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSecondary Progressive Multiple SclerosisInterventionBlood Draw; CSF collection by lumbar puncture (Optional)PhaseNot recordedRegistry statusCompletedSafety and Efficacy of BAF312 in Dermatomyositis
NCT02029274 · start 2013-08-25
Registered record
- Registry ID
- NCT02029274
- Conditions
- Active Dermatomyositis
- Interventions
- BAF312; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2013-08-25
- Completion
- 2016-02-17
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActive DermatomyositisInterventionBAF312; PlaceboPhasePhase 2Registry statusTerminatedA Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
NCT01904214 · start 2013-07
Registered record
- Registry ID
- NCT01904214
- Conditions
- Renal Impairment
- Interventions
- BAF312
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2014-11
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal ImpairmentInterventionBAF312PhasePhase 1Registry statusCompletedEfficacy and Tolerability of BAF312 in Patients With Polymyositis
NCT01801917 · start 2013-04-24
Registered record
- Registry ID
- NCT01801917
- Conditions
- Polymyositis
- Interventions
- Placebo; BAF312
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2013-04-24
- Completion
- 2016-08-05
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolymyositisInterventionPlacebo; BAF312PhasePhase 2Registry statusTerminatedExploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
NCT01665144 · start 2012-12-20
Registered record
- Registry ID
- NCT01665144
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- BAF312; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-12-20
- Completion
- 2023-03-31
- Enrolment
- 1,651
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSecondary Progressive Multiple SclerosisInterventionBAF312; PlaceboPhasePhase 3Registry statusCompletedPharmacokinetics of BAF312 in Patients With Hepatic Impairment
NCT01565902 · start 2012-10
Registered record
- Registry ID
- NCT01565902
- Conditions
- Hepatic Impairment
- Interventions
- BAF312
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2014-03
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic ImpairmentInterventionBAF312PhasePhase 1Registry statusCompletedLong-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
NCT01185821 · start 2010-08-30
Registered record
- Registry ID
- NCT01185821
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- BAF312
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-08-30
- Completion
- 2016-10-10
- Enrolment
- 185
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsing Remitting Multiple SclerosisInterventionBAF312PhasePhase 2Registry statusCompletedEfficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
NCT01148810 · start 2010-06-15
Registered record
- Registry ID
- NCT01148810
- Conditions
- Polymyositis; Dermatomyositis
- Interventions
- BAF312; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2010-06-15
- Completion
- 2012-06-13
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPolymyositis; DermatomyositisInterventionBAF312; PlaceboPhasePhase 2Registry statusTerminatedSafety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
NCT00879658 · start 2009-03-30
Registered record
- Registry ID
- NCT00879658
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- BAF312; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-03-30
- Completion
- 2011-05-04
- Enrolment
- 297
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsing-remitting Multiple SclerosisInterventionBAF312; PlaceboPhasePhase 2Registry statusCompleted